Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer

Tung H. Ng,
Kathy W. Y. Sham,
Chuan M. Xie,
Simon S. M. Ng,
Ka F. To,
Joanna H. M. Tong,
Wing Y. Z. Liu,
Lin Zhang,
Matthew T. V. Chan,
William K. K. WuEmail author and
Christopher H. K. ChengEmail author

BMC Cancer201919:649

https://doi.org/10.1186/s12885-019-5873-0

Received: 29 January 2019
Accepted: 24 June 2019
Published: 2 July 2019

Open Peer Review reports

Abstract

Background

Prognostication of patients with colorectal cancer (CRC) currently relies on tumor-node-metastasis (TNM) staging but clinical outcomes of patients of the same histoclinical stage are heterogeneous. It is therefore imperative to devise novel molecular tests to stratify CRC patients. Our previous work demonstrated that eukaryotic elongation factor-2 kinase (EEF2K) is a tumor suppressor in CRC. Herein, we investigated EEF2K expression in CRC and determined its relationship with clinicopathological parameters.

Methods

Quantitative RT-PCR and Westerns blots were used to examine EEF2K expression in primary tumor and the adjacent non-tumor tissues of CRC patients (n = 20). Kaplan-Meier curves and Cox regression analysis were used to assess the association between clinical outcomes of CRC patients and EEF2K protein expression determined by immunohistochemistry on tissue microarray (n = 151).

Results

EEF2K was significantly downregulated at both mRNA and protein levels in tumors of CRC patients. Univariate Cox regression analysis revealed that CRC patients with high tumor grade, advanced TNM staging and low EEF2K expression were associated with worse overall survival. Multivariate analysis further demonstrated that low EEF2K expression was an independent factor for predicting poorer overall survival in CRC patients (p = 0.014; Hazard ratio = 2.951; 95% confidence interval: 1.240–7.024). The 5-year survival rate was 82.8% in the EEF2K-high-expression group versus 63.9% in the EEF2K-low-expression group (p = 0.0118). The association of overall survival with EEF2K expression in CRC patients was verified in The Cancer Genome Atlas (TCGA) cohort.